Cogent Biosciences, Inc.
Income Statement
| Line Item | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Product | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| License | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Cost of Revenue | — | — | — | — | — | — | — | — |
| Gross Profit | — | — | — | — | — | — | — | — |
| Gross Margin | — | — | — | — | — | — | — | — |
| Operating Expenses | ||||||||
| Research & Development | $173.8M | $121.6M | $55.9M | $25.7M | $43.7M | $38.3M | $29.8M | — |
| SG&A Expense | $34.4M | $26.2M | $19.6M | $17.4M | $11.0M | $7.5M | $4.7M | — |
| Operating Income | $-208.1M | $-147.8M | $-75.6M | $-82.2M | $-32.2M | $-36.0M | $-26.2M | — |
| Operating Margin | — | — | — | — | — | — | — | — |
| Interest Expense | — | — | — | — | — | — | — | — |
| Pretax Income | — | — | — | — | — | — | — | — |
| Income Tax Expense | — | — | — | — | — | — | — | — |
| Net Income | $-192.4M | $-140.2M | $-72.3M | $-74.8M | $-31.8M | $-34.5M | $-25.5M | — |
| Net Margin | — | — | — | — | — | — | — | — |
| EPS (Basic) | $-1.94 | $-1.73 | $-1.87 | $-16.17 | $-4.18 | $-1.39 | $-2.51 | — |
| EPS (Diluted) | $-1.94 | $-1.73 | $-1.87 | $-16.17 | $-4.18 | $-1.39 | $-2.51 | — |
| Shares Outstanding (Basic) | 79.7M | 58.7M | 38.7M | 32.3M | 7.7M | 30.1M | 10.2M | — |
| Shares Outstanding (Diluted) | 79.7M | 58.7M | 38.7M | 32.3M | 7.7M | 30.1M | 10.2M | — |
| Dividends Per Share | — | — | — | — | — | — | — | — |